Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
H Rabinowich, … , M C Bell, T L Whiteside
H Rabinowich, … , M C Bell, T L Whiteside
Published June 1, 1998
Citation Information: J Clin Invest. 1998;101(11):2579-2588. https://doi.org/10.1172/JCI1518.
View: Text | PDF
Research Article Article has an altmetric score of 3

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.

  • Text
  • PDF
Abstract

We have recently reported that tumor-associated lymphocytes obtained from ascitic fluids of women with ovarian carcinoma (OvCA) demonstrate a marked decrease in expression of cytoplasmic CD3-zeta and surface CD3-epsilon chains, which is associated with altered function of T cell receptor (TcR). We now demonstrate that OvCAs in situ and in culture express functional Fas ligand (FasL), capable of triggering an intrinsic cell death program in Fas-expressing T cells. The possibility of a relationship between cell death and altered expression of TcR was examined. The data indicate that alterations in expression of CD3-zeta and CD3-epsilon chains in T cells coincubated with OvCA are related to tumor-induced apoptosis, as the addition of pan-caspase inhibitors, DEVD-cho or YVAD-cho, prevents both the in vitro induction of T cell death by OvCA cells and the changes in the level of expression of CD3-zeta and CD3-epsilon chains. In the presence of Fas-Fc fusion protein, but not Fc-control protein, the loss in expression of CD3-zeta and CD3-epsilon chains induced in T cells by FasL+ OvCA cells was prevented. These results suggest that the loss in expression of CD3-zeta and CD3-epsilon chains in T lymphocytes interacting with OvCA cells is associated with apoptosis mediated by FasL-expressing tumor cells.

Authors

H Rabinowich, T E Reichert, Y Kashii, B R Gastman, M C Bell, T L Whiteside

×

Total citations by year

Year: 2024 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1976 Total
Citations: 2 3 3 1 1 2 2 3 2 6 5 5 6 6 7 6 15 20 15 11 15 8 1 145
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (145)

Title and authors Publication Year
Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function
Degirmencay A, Thomas S, Holler A, Burgess S, Morris EC, Stauss HJ
Frontiers in immunology 2024
FASLG as a Key Member of Necroptosis Participats in Acute Myocardial Infarction by Regulating Immune Infiltration
Jia HM, An FX, Zhang Y, Yan MZ, Zhou Y, Bian HJ
Cardiology Research 2024
Genetic Polymorphism and cancer susceptibility
AS Sameer, MZ Banday, S Nissar
2021
The Proposition of the Pulmonary Route as an Attractive Drug Delivery Approach of Nano-Based Immune Therapies and Cancer Vaccines to Treat Lung Tumors
M Donkor, HP Jones
2021
Immunotyping in tubo‐ovarian high‐grade serous carcinoma by PD‐L1 and CD8+ T‐lymphocytes predicts disease‐free survival
A Bansal, R Srinivasan, M Rohilla, B Rai, A Rajwanshi, V Suri, SC Saha
APMIS 2021
Myeloid Cell-Derived Arginase in Cancer Immune Response
TM Grzywa, A Sosnowska, P Matryba, Z Rydzynska, M Jasinski, D Nowis, J Golab
Frontiers in immunology 2020
Antitumour dendritic cell vaccination in a priming and boosting approach
A Harari, M Graciotti, M Bassani-Sternberg, LE Kandalaft
Nature Reviews Drug Discovery 2020
Defects at the Posttranscriptional Level Account for the Low TCRζ Chain Expression Detected in Gastric Cancer Independently of Caspase-3 Activity
A Aguinaga-Barrilero, P Castro-Sánchez, I Juárez, A Gutiérrez-Calvo, N Rodríguez-Pérez, A Lopez, R Gómez, JM Martin-Villa, P Wlasiuk
Journal of Immunology Research 2020
CD247 expression is associated with differentiation and classification in ovarian cancer:
W Ye, Y Zhou, B Xu, D Zhu, X Rui, M Xu, L Shi, D Zhang, J Jiang
Medicine 2019
The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia
FR Villagomez, O Medina-Contreras, JF Cerna-Cortes, G Patino-Lopez
Small GTPases 2018
Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma
C Cai, J Zhang, M Li, ZJ Wu, KH Song, TW Zhan, LH Wang, YH Sun
Tumor Biology 2015
Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer
Guang-Zhou Wu, Chun-Xia Pan, Dong Jiang, Qiang Zhang, Yin Li, Shi-Ying Zheng
American journal of cancer research 2015
Association of the Polymorphisms in the Fas/FasL Promoter Regions with Cancer Susceptibility: A Systematic Review and Meta-Analysis of 52 Studies
Y Xu, B He, R Li, Y Pan, T Gao, Q Deng, H Sun, G Song, S Wang, QY Wei
PloS one 2014
Fas −670A/G (rs1800682) Polymorphism and Digestive Cancer Risk in Asians: A Meta-Analysis
HP Yuan, QD Liu, GQ Li, YQ Cong
Genetic Testing and Molecular Biomarkers 2014
Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population
J Wang, J Gao, Y Li, X Zhao, W Gao, L Peng, D Yan, L Liu, D Li, L Wei, J Qi, C Zhou
Gene 2013
Fas ligand+ fallopian tube epithelium induces apoptosis in both Fas receptor+ T lymphocytes and endometrial cells
SE Illanes, K Maisey, M Sandoval, FE Reyes, C Figueroa-Gaete, A Pérez-Sepúlveda, M Busquets, P González, M Imarai
Fertility and Sterility 2013
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
LE Kandalaft, CL Chiang, J Tanyi, G Motz, K Balint, R Mick, G Coukos
Journal of Translational Medicine 2013
Expression of co-stimulators CD28/B7-1 in peripheral blood of patients with breast cancer
J Gong, W Pan, C Yang, F Guo, Y Sun
Breast Cancer Research and Treatment 2012
Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes
Y Li, Y Hao, S Kang, R Zhou, N Wang, B Qi
Gynecologic Oncology 2012
Human FasL Gene Is a Target of β-Catenin/T-Cell Factor Pathway and Complex FasL Haplotypes Alter Promoter Functions
J Wu, MH Richards, J Huang, L Al-Harthi, X Xu, R Lin, F Xie, AW Gibson, JC Edberg, RP Kimberly, C Gottardi
PloS one 2011
Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy
VT Cheriyan, C Thomas, P Balaram
Journal of Cancer Research and Clinical Oncology 2011
Attack the Tumor Counterattack-C-Flip Expression in Jurkat-T-Cells Protects Against Apoptosis Induced by Coculture with SW620 Colorectal Adenocarcinoma Cells
AE Steiert, D Sendler, WF Burke, CY Choi, K Reimers, PM Vogt
Journal of Surgical Research 2011
Interleukin-13 Induces T Helper Type 2 Immune Responses in OVA-Immunized BALB/c Mice Bearing a T Cell Lymphoma : IL-13 Induces Th2 Type Immune Responses
P Deepak, A Acharya
Scandinavian Journal of Immunology 2011
Cancer of the Skin
B Berman, M Viera, S Amini, W Valins
Cancer of the Skin 2011
Cell Signaling & Molecular Targets in Cancer
M Chatterjee, K Kashfi
2011
Whole tumor antigen vaccines
CL Chiang, F Benencia, G Coukos
Seminars in Immunology 2010
CD95 promotes tumour growth
L Chen, SM Park, AV Tumanov, A Hau, K Sawada, C Feig, JR Turner, YX Fu, IL Romero, E Lengyel, ME Peter
Nature 2010
The role of immunity in elderly cancer
L Malaguarnera, E Cristaldi, M Malaguarnera
Critical Reviews in Oncology/Hematology 2010
Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma
J Zhu, C Qin, M Wang, F Yan, X Ju, X Meng, Q Ding, P Li, J Yang, Q Cao, Z Zhang, C Yin
Molecular Carcinogenesis 2010
Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma
RM Zhou, N Wang, ZF Chen, YN Duan, DL Sun, Y Li
Journal of Gastroenterology and Hepatology 2010
Tumor-Shed PGE2 Impairs IL2Rγc-Signaling to Inhibit CD4+ T Cell Survival: Regulation by Theaflavins
S Chattopadhyay, S Bhattacharyya, B Saha, J Chakraborty, S Mohanty, DM Hossain, S Banerjee, K Das, G Sa, T Das, JA Bauer
PloS one 2009
Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients
WK Yip, MA Abdullah, SM Yusoff, HF Seow
Clinical & Experimental Immunology 2009
Tricks tumors use to escape from immune control
TL Whiteside
Oral Oncology 2009
T Cell Density and Location Can Influence the Prognosis of Ovarian Cancer
A Al-Attar, M Shehata, L Durrant, P Moseley, S Deen, S Chan
Pathology & Oncology Research 2009
Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer
AE Albers, C Schaefer, C Visus, W Gooding, AB DeLeo, TL Whiteside
Head & Neck 2009
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
PC Rodríguez, AC Ochoa
Immunological Reviews 2008
Cancer Immunology
OJ Finn
New England Journal of Medicine 2008
The impact of T-cell immunity on ovarian cancer outcomes
BH Nelson
Immunological Reviews 2008
Modulation of cell growth and apoptosis response in human prostate cancer cells supplemented with tocotrienols
K Nesaretnam, TH Koon, KR Selvaduray, RS Bruno, E Ho
European Journal of Lipid Science and Technology 2008
Innate and Adaptive Immunity in the Tumor Microenvironment
E Yefenof
2008
Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways
T Das, G Sa, E Paszkiewicz-Kozik, C Hilston, L Molto, P Rayman, D Kudo, K Biswas, RM Bukowski, JH Finke, CS Tannenbaum
Journal of immunology (Baltimore, Md. : 1950) 2008
The Role of Death Receptor Ligands in Shaping Tumor Microenvironment
TL Whiteside
Immunological Investigations 2007
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
V Minas, A Rolaki, SN Kalantaridou, J Sidiropoulos, S Mitrou, G Petsas, U Jeschke, EA Paraskevaidis, G Fountzilas, GP Chrousos, N Pavlidis, A Makrigiannakis
British Journal of Cancer 2007
Cancer Immunotherapy
S Mandruzzato, S Mocellin, V Bronte
Cancer Immunotherapy 2007
Curcumin Prevents Tumor-induced T Cell Apoptosis through Stat-5a-mediated Bcl-2 Induction
S Bhattacharyya, D Mandal, B Saha, GS Sen, T Das, G Sa
The Journal of biological chemistry 2007
General Principles of Tumor Immunotherapy
HL Kaufman, JD Wolchok
2007
Phosphatidylinositol 3-Kinase/Akt Activation by Integrin-Tumor Matrix Interaction Suppresses Fas-Mediated Apoptosis in T Cells
CC Su, YP Lin, YJ Cheng, JY Huang, WJ Chuang, YS Shan, BC Yang
Journal of immunology (Baltimore, Md. : 1950) 2007
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
MG Hanson, V Özenci, MC Carlsten, BL Glimelius, JE Frödin, G Masucci, KJ Malmberg, RV Kiessling
Cancer Immunology, Immunotherapy 2006
The cancer stem cell: evidence for its origin as an injured autoreactive T cell
P Grandics
Molecular Cancer 2006
The tumour microenvironment and implications for cancer immunotherapy
CA Petrulio, S Kim-Schulze, HL Kaufman
Expert Opinion on Biological Therapy 2006
Tumor immune escape mechanisms: impact of the neuroendocrine system
K Lang, F Entschladen, C Weidt, KS Zaenker
Cancer Immunology, Immunotherapy 2006
HSP-10 in ovarian cancer: Expression and suppression of T-cell signaling
S Akyol, C Gercel-Taylor, LC Reynolds, DD Taylor
Gynecologic Oncology 2006
Tumor Infiltrating Lymphocytes in Uveal Melanoma: A Link with Clinical Behavior?
S Staibano, M Mascolo, F Tranfa, G Salvatore, C Mignogna, P Bufo, L Nugnes, G Bonavolontà, GD Rosa
International journal of immunopathology and pharmacology 2006
Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling
DD Taylor, S Akyol, C Gercel-Taylor
Journal of immunology (Baltimore, Md. : 1950) 2006
Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects
DD Taylor, C Gerçel-Taylor
British Journal of Cancer 2005
Current concepts of tumor-infiltrating lymphocytes in human malignancies
SH Chiou, BC Sheu, WC Chang, SC Huang, H Hong-Nerng
Journal of Reproductive Immunology 2005
Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer
K Sonoda, S Miyamoto, T Hirakawa, H Yagi, F Yotsumoto, M Nakashima, T Watanabe, H Nakano
Gynecologic Oncology 2005
FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer
T Sun, Y Zhou, H Li, X Han, Y Shi, L Wang, X Miao, W Tan, D Zhao, X Zhang, Y Guo, D Lin
Journal of Experimental Medicine 2005
Tumor Immunology and Cancer Vaccines
SN Khleif
2005
Apoptosis of Lymphocytes in Peripheral Blood of Patients with Melanoma
F Tas, D Duranyildiz, A Argon, H Oguz, H Camlica, V Yasasever, E Topuz
Medical Oncology 2005
Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells
JR Conejo-Garcia, F Benencia, MC Courreges, PA Gimotty, E Khang, RJ Buckanovich, KA Frauwirth, L Zhang, D Katsaros, CB Thompson, B Levine, G Coukos
Cancer research 2004
CD95L mediates tumor counterattackin vitro but induces neutrophil-independent tumor rejectionin vivo
FH Igney, CK Behrens, PH Krammer
International Journal of Cancer 2004
Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma
AC Satchell, RS Barnetson, GM Halliday
British Journal of Dermatology 2004
Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
AD Santin, S Bellone, M Palmieri, B Bossini, S Cane', E Bignotti, JJ Roman, MJ Cannon, S Pecorelli
International Journal of Gynecological Cancer 2004
Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients
A Maki, M Matsuda, M Asakawa, H Kono, H Fujii, Y Matsumoto
Journal of Gastroenterology and Hepatology 2004
Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer
H Sugai, K Kono, A Takahashi, F Ichihara, H Kawaida, H Fujii, Y Matsumoto
Journal of Surgical Research 2004
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes
Y Meng, L Graves, TV Do, J So, DA Fishman
Gynecologic Oncology 2004
Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions
JJ Sikora, GT Dworacki, MT Kaczmarek, RE Jenek, JO Żeromski
Cancer Detection and Prevention 2004
Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients
DD Taylor, RP Edwards, CR Case, Ç Gerçel-Taylor
Gynecologic Oncology 2004
The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack
MJ Martı́nez-Lorenzo, A Anel, MA Alava, A Piñeiro, J Naval, P Lasierra, L Larrad
Experimental Cell Research 2004
Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes
A Riccobon, R Gunelli, R Ridolfi, FD Paola, E Flamini, M Fiori, C Saltutti, M Petrini, L Fiammenghi, M Stefanelli, AM Granato, DE Cuzzocrea, D Amadori
Cancer Investigation 2004
Cancer Immunotherapy at the Crossroads
JH Finke, RM Bukowski
2004
Characterization of Defective CD4 − CD8 − T Cells in Murine Tumors Generated Independent of Antigen Specificity
RM Prins, F Incardona, R Lau, P Lee, S Claus, W Zhang, KL Black, CJ Wheeler
Journal of immunology (Baltimore, Md. : 1950) 2004
Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer?
Whiteside TL
Cancer Immunology, Immunotherapy 2004
Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape?
Malmberg KJ
Cancer Immunology, Immunotherapy 2004
The Fas/Fas Ligand System and Cancer: Immune Privilege and Apoptosis
VM Abrahams, M Kamsteeg, G Mor
Molecular Biotechnology 2003
Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck
I Kuss, AD Donnenberg, W Gooding, TL Whiteside
British Journal of Cancer 2003
Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
FD Paola, R Ridolfi, A Riccobon, E Flamini, F Barzanti, AM Granato, GL Mordenti, L Medri, P Vitali, D Amadori
British Journal of Cancer 2003
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
L Zhang, JR Conejo-Garcia, D Katsaros, PA Gimotty, M Massobrio, G Regnani, A Makrigiannakis, H Gray, K Schlienger, MN Liebman, SC Rubin, G Coukos
New England Journal of Medicine 2003
Human Urinary Bladder Transitional Cell Carcinomas Acquire the Functional Fas Ligand during Tumor Progression
D Chopin, R Barei-Moniri, P Maillé, MA Frère-Belda, B Muscatelli-Groux, N Merendino, L Lecerf, A Stoppacciaro, F Velotti
The American Journal of Pathology 2003
Cancer Chemotherapy and Biological Response Modifiers Annual
MS Turner, JR McKolanis, RK Ramanathan, DC Whitcomb, OJ Finn
Cancer Chemotherapy and Biological Response Modifiers Annual Volume 21 2003
Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium
JS Yu, PK Lee, M Ehtesham, K Samoto, KL Black, CJ Wheeler
Journal of Neuro-Oncology 2003
Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer:
KM Sheehan, DG O'Donovan, G Fitzmaurice, A O'Grady, DP O'Donoghue, K Sheahan, MF Byrne, RM Conroy, EW Kay, FE Murray
European Journal of Gastroenterology & Hepatology 2003
Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment
L Pignataro, E Arisi, G Sambataro, MM Corsi
Journal of Surgical Oncology 2003
Covalent linking of proteins and cytokines to suture: Enhancing the immune response of head and neck cancer patients
TY Shibuya, S Kim, K Nguyen, P Parikh, A Wadhwa, C Brockardt, J Do
The Laryngoscope 2003
Expression of Fas and FasL in human serous ovarian epithelial tumors
C Haaften-Day, P Russell, S Davies, NJ King, MH Tattersall
Human Pathology 2003
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia
GF Torelli, R Paolini, C Tatarelli, A Soriani, A Vitale, A Guarini, A Santoni, R Foa
British Journal of Haematology 2003
Immunologic principles and immunotherapeutic approaches in ovarian cancer
Keith L Knutson, Tyler J Curiel, Lupe Salazar, Mary L Disis
Hematology/Oncology Clinics of North America 2003
Regulation of FasL/Fas in Human Trophoblasts: Possible Implications for Chorioamnionitis1
DR Balkundi, JA Ziegler, JF Watchko, C Craven, M Trucco
Biology of reproduction 2003
Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
FD Paola, R Ridolfi, A Riccobon, E Flamini, F Barzanti, AM Granato, GL Mordenti, L Medri, P Vitali, D Amadori
British Journal of Cancer 2003
Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck
I Kuss, AD Donnenberg, W Gooding, TL Whiteside
British Journal of Cancer 2003
Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer
A Takahashi, K Kono, F Ichihara, H Sugai, H Amemiya, H Iizuka, H Fujii, Y Matsumoto
International Journal of Cancer 2003
Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium.
Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ
Journal of Neuro-Oncology 2003
Tumour escape: antitumour effectors too much of a good thing?
Pawelec G
Cancer Immunology, Immunotherapy 2003
Rapid turnover of the CD8+CD28- T-cell subset of effector cells in the circulation of patients with head and neck cancer
Tsukishiro T, Donnenberg AD, Whiteside TL
Cancer Immunology, Immunotherapy 2003
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
KJ Malmberg, V Levitsky, H Norell, CT de Matos, M Carlsten, K Schedvins, H Rabbani, A Moretta, K Söderström, J Levitskaya, R Kiessling
Journal of Clinical Investigation 2002
Fas receptor-mediated apoptosis: a clinical application?
T Timmer, EG de Vries, S Jong
The Journal of Pathology 2002
Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer
N Meidenbauer, W Gooding, L Spitler, D Harris, TL Whiteside
British Journal of Cancer 2002
Modulation of T-cell CD3-zeta chain expression during normal pregnancy
DD Taylor, SA Sullivan, AC Eblen, C Gercel-Taylor
Journal of Reproductive Immunology 2002
Shed membrane fragment modulation of CD3-zeta during pregnancy: link with induction of apoptosis
C Gercel-Taylor, SM O'Connor, GK Lam, DD Taylor
Journal of Reproductive Immunology 2002
The biological role of the Fas/FasL system during tumor formation and progression
E Reichmann
Seminars in Cancer Biology 2002
Expression of Functional Fas Ligand in Choriocarcinoma
A Hammer, M Hartmann, P Sedlmayr, W Walcher, G Kohnen, G Dohr
American Journal of Reproductive Immunology 2002
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) expression
HR Salih, GC Starling, SF Brandl, R Pelka-Fleischer, T Haferlach, W Hiddemann, PA Kiener, V Nuessler
British Journal of Haematology 2002
Expression of the signal transduction molecule zeta in peripheral and tumour-associated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr virus status of the tumour cells
J Sjoberg, M Andersson, C Garcia, KA Palucka, M Bjorkholm, A Porwit-MacDonald, P Pisa
British Journal of Haematology 2002
Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy
TL Whiteside
Vaccine 2002
Expression of ζ in T Cells Prior to Interleukin-2 Therapy as a Predictor of Response and Survival in Patients with Ovarian Carcinoma
I Kuss, H Rabinowich, W Gooding, R Edwards, TL Whiteside
Cancer Biotherapy & Radiopharmaceuticals 2002
Tumor-induced death of immune cells: its mechanisms and consequences
TL Whiteside
Seminars in Cancer Biology 2002
CD3-?chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients
S Ishigami, S Natsugoe, K Tokuda, A Nakajo, H Higashi, H Iwashige, K Aridome, S Hokita, T Aikou
Cancer 2002
Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer
M Ehtesham, K Samoto, P Kabos, FL Acosta, MA Gutierrez, KL Black, JS Yu
Cancer Gene Therapy 2002
Cancer vaccines and immunotherapy
S Dermime, A Armstrong, RE Hawkins, PL Stern
British Medical Bulletin 2002
Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients
DD Taylor, DP Bender, GT C, J Stanson, TL Whiteside
British Journal of Cancer 2001
The role of Fas and FasL as mediators of anticancer chemotherapy
V Poulaki, CS Mitsiades, N Mitsiades
Drug Resistance Updates 2001
Apoptosis and its clinical impact
BR Gastman
Head & Neck 2001
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug
N Mitsiades, KC Anderson, V Poulaki, CS Mitsiades
Expert Opinion on Investigational Drugs 2001
Head and Neck Cancer
A Forastiere, W Koch, A Trotti, D Sidransky
New England Journal of Medicine 2001
Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression
MH Andersen, P Keikavoussi, EB Br�cker, B Schuler-Thurner, M Jonassen, I S�ndergaard, P Straten, JC Becker, E K�mpgen
International Journal of Cancer 2001
Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer
AD Santin, S Bellone, A Ravaggi, J Roman, CV Smith, S Pecorelli, MJ Cannon, GP Parham
BJOG: An International Journal of Obstetrics and Gynaecology 2001
Loss of T-cell receptor-CD3ζ and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma
DC Lockhart, AK Chan, S Mak, HG Joo, HA Daust, A Carritte, CC Douville, PS Goedegebuure, TJ Eberlein
Surgery 2001
Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer
AD Santin, S Bellone, A Ravaggi, J Roman, CV Smith, S Pecorelli, MJ Cannon, GP Parham
British Journal of Obstetrics and Gynaecology 2001
Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95-Sensitive Cells
HR Salih, GC Starling, M Knauff, MB Llewellyn, PM Davis, WJ Pitts, A Aruffo, PA Kiener
Experimental Cell Research 2001
CD8 + Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ
S Radoja, M Saio, AB Frey
Journal of immunology (Baltimore, Md. : 1950) 2001
Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis
X Chen, A Woiciechowsky, S Raffegerst, D Schendel, HJ Kolb, M Roskrow
British Journal of Haematology 2000
CD95 ligand expression as a mechanism of immune escape in breast cancer
M Müschen, C Moers, U Warskulat, J Even, D Niederacher, MW Beckmann
Immunology 2000
Nonlymphoid cultured cells possess a system controlling cellular compatibility
LP Sashchenko, EA Dukhanina, ES Ioudinkova, OV Iarovaia, TI Lukianova, OD Kabanova, NV Gnuchev, SV Razin
Journal of Cellular Biochemistry 2000
Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell Death
W Stohl, D Xu, GC Starling, P Casali, PA Kiener
Cellular Immunology 2000
Immunology and immunotherapy of human cancer: present concepts and clinical developments
AJ Bremers, G Parmiani
Critical Reviews in Oncology/Hematology 2000
Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
K Hellstrand, M Brune, C Dahlgren, M Hansson, S Hermodsson, P Lindnér, UH Mellqvist, P Naredi
Medical Oncology 2000
Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events
BR Gastman, DE Johnson, TL Whiteside, H Rabinowich
Blood 2000
Circulating soluble Fas ligand in patients with gastric carcinoma
S Tsutsumi, H Kuwano, T Shimura, N Morinaga, E Mochiki, T Asao
Cancer 2000
B7.1 on Human Carcinomas: Costimulation of T Cells and Enhanced Tumor-Induced T-Cell Death
S Lang, Y Atarashi, Y Nishioka, J Stanson, N Meidenbauer, TL Whiteside
Cellular Immunology 2000
Antigen-Specific Induction of Peripheral T Cell Tolerance in Vivo by Codelivery of DNA Vectors Encoding Antigen and Fas Ligand
RW Georgantas, KW Leong, JT August
Human Gene Therapy 2000
Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen
G Mor, F Kohen, J Garcia-Velasco, J Nilsen, W Brown, J Song, F Naftolin
The Journal of Steroid Biochemistry and Molecular Biology 2000
Specificity questions concerning the clone 33 anti-fas ligand antibody
JR Baker, JD Bretz
Cell Death and Differentiation 2000
Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing
S Radoja, AB Frey
Molecular Medicine 2000
Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway
N Favre-Felix, A Fromentin, A Hammann, E Solary, F Martin, B Bonnotte
Journal of immunology (Baltimore, Md. : 1950) 2000
Type 1 and Type 2 CD8 + Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor
MJ Dobrzanski, JB Reome, RW Dutton
Journal of immunology (Baltimore, Md. : 1950) 2000
Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack
O'connell, Bennett, O'sullivan, Collins, Shanahan
Diseases of the Esophagus 1999
Fas-Mediated Induction of Hepatocyte Apoptosis in a Neuroblastoma and Hepatocyte Coculture Model
MK Chen, LF Strande, EA Beierle, MS Kain, BD Geldziler, EJ Doolin
Journal of Surgical Research 1999
Alterations in NF B Activation in T Lymphocytes of Patients With Renal Cell Carcinoma
RG Uzzo, PE Clark, P Rayman, T Bloom, L Rybicki, AC Novick, RM Bukowski, JH Finke
JNCI Journal of the National Cancer Institute 1999
Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors
N Mitsiades, V Poulaki, A Leone, M Tsokos
JNCI Journal of the National Cancer Institute 1999
The Fas counterattack: cancer as a site of immune privilege
J O’Connell, MW Bennett, GC O’Sullivan, JK Collins, F Shanahan
Immunology Today 1999
FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection
N Favre, B Bonnotte, N Droin, A Fromentin, E Solary, F Martin
International Journal of Cancer 1999
Tumor Necrosis Factor-α and Interferon-γ Induce Expression of Functional Fas Ligand on HT29 and MCF7 Adenocarcinoma Cells
C Naujokat, O Sezer, K Possinger
Biochemical and Biophysical Research Communications 1999
Predominant Expression of Fas (CD95) Ligand in Metastatic Melanoma Revealed by Longitudinal Analysis
P Terheyden, C Siedel, A Merkel, E Kampgen, EB Brocker, JC Becker
Journal of Investigative Dermatology 1999
Immunology for Surgeons
JE Castro
1976

← Previous 1 2 3 4 5 6 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
32 readers on Mendeley
See more details